Stonehage Fleming Financial Services’s Vertex Pharmaceuticals VRTX Stock Holding History

Stonehage Fleming Financial Services’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-3,000	Closed	-$552K	–	185
2019 Q1	$552K	Hold	3,000	–	–	0.03%	96
2018 Q4	$497K	Hold	3,000	–	–	0.03%	106
2018 Q3	$578K	Hold	3,000	–	–	0.03%	103
2018 Q2	$510K	Sell	3,000 -1,000	-25%	-$155K	0.02%	124
2018 Q1	$652K	Hold	4,000	–	–	0.04%	94
2017 Q4	$599K	Hold	4,000	–	–	0.03%	115
2017 Q3	$608K	Hold	4,000	–	–	0.03%	127
2017 Q2	$515K	Hold	4,000	–	–	0.03%	131
2017 Q1	$437K	Hold	4,000	–	–	0.03%	173
2016 Q4	$295K	Sell	4,000 -343	-8%	-$27.9K	0.02%	194
2016 Q3	$379K	Buy	4,343 +343	+9%	+$32.4K	0.02%	160
2016 Q2	$344K	Buy	+4,000	New	+$346K	0.02%	158

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Stonehage Fleming Financial Services's VRTX Position: Q2 2019 in Review

Stonehage Fleming Financial Services sold out of Vertex Pharmaceuticals (VRTX) in Q2 2019, closing a stake of 3,000 shares — an estimated $552K sold.

Stonehage Fleming Financial Services first reported a position in VRTX in Q2 2016 and held it in 12 quarters. The position peaked at $652K in Q1 2018. 716 funds tracked by Wall St. Rank hold VRTX as of Q2 2019.

Stonehage Fleming Financial Services reported no remaining Vertex Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Stonehage Fleming Financial Services sold 3,000 Vertex Pharmaceuticals shares in Q2 2019, an estimated $552K.
Stonehage Fleming Financial Services first reported a position in Vertex Pharmaceuticals in Q2 2016 and held it in 12 quarters.
Stonehage Fleming Financial Services's Vertex Pharmaceuticals position peaked at $652K in Q1 2018.
716 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2019.

Based on Stonehage Fleming Financial Services's 13F filing for Q2 2019, filed 3 Sep 2019.